Abbott Laboratories (ABT)vsPDD Holdings Inc. (PDD)
ABT
Abbott Laboratories
$84.32
-3.09%
HEALTHCARE · Cap: $151.56B
PDD
PDD Holdings Inc.
$98.78
-2.69%
CONSUMER CYCLICAL · Cap: $145.63B
Smart Verdict
WallStSmart Research — data-driven comparison
PDD Holdings Inc. generates 857% more annual revenue ($431.85B vs $45.13B). PDD leads profitability with a 22.7% profit margin vs 13.9%. PDD appears more attractively valued with a PEG of 0.70. PDD earns a higher WallStSmart Score of 75/100 (B+).
ABT
Buy56
out of 100
Grade: C
PDD
Strong Buy75
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+0.6%
Fair Value
$87.53
Current Price
$84.32
$3.21 discount
Margin of Safety
+78.0%
Fair Value
$485.14
Current Price
$98.78
$386.36 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Generating 24.1B in free cash flow
Large-cap with strong market position
Every $100 of equity generates 27 in profit
Keeps 23 of every $100 in revenue as profit
Areas to Watch
Weak financial health signals
Earnings declined 19.7%
Weak financial health signals
Earnings declined 16.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.
Bull Case : PDD
The strongest argument for PDD centers on P/E Ratio, Debt/Equity, Free Cash Flow. Profitability is solid with margins at 22.7% and operating margin at 21.1%. Revenue growth of 12.0% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are Piotroski F-Score, EPS Growth.
Bear Case : PDD
The primary concerns for PDD are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ABT profiles as a value stock while PDD is a mature play — different risk/reward profiles.
ABT carries more volatility with a beta of 0.65 — expect wider price swings.
PDD is growing revenue faster at 12.0% — sustainability is the question.
PDD generates stronger free cash flow (24.1B), providing more financial flexibility.
Bottom Line
PDD scores higher overall (75/100 vs 56/100), backed by strong 22.7% margins and 12.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →PDD Holdings Inc.
CONSUMER CYCLICAL · INTERNET RETAIL · China
Pinduoduo Inc., operates an electronic commerce platform in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?